Dermatology

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

The FDA has accepted LEO Pharma's sNDA for delgocitinib cream for moderate-to-severe chronic hand eczema in adolescents.

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

This interview with Stephan Weidinger, MD, PhD, at AAD 2026 highlights new data on lebrikizumab

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.

During this video interview at AAD 2026, Gold touches on key points made in his session titled ‘Complications of Cosmetic Procedures.’

These new dermatology guidelines represent the first-ever atopic dermatitis-centered guidelines for pediatric patients issued by the AAD.

This review of dermatology news from the first quarter of 2026 highlights key headlines, FDA news, and more.

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

In this Q&A interview at AAD 2026, Gold highlights various tips and strategies for healing scars among patients with skin of color.

This Q&A interview with Gold at AAD 2026 highlights notable takeaways from his portion of the session titled 'Acne Boot Camp.'

This summary of March 2026 highlights key news and developments in the dermatology news space.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

This Q&A interview at AAD 2026 highlights health information technologies and AI tools used in dermatology practices.